Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands

INTRODUCTION: Insulin degludec/liraglutide (IDegLira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (T2DM) who are uncontrolled on basal insulin and req...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Barnaby, Glah, Divina, van der Vliet, Maarten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544604/
https://www.ncbi.nlm.nih.gov/pubmed/28523483
http://dx.doi.org/10.1007/s13300-017-0266-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544604/
https://www.ncbi.nlm.nih.gov/pubmed/28523483
http://dx.doi.org/10.1007/s13300-017-0266-3

Ejemplares similares